In a latest update, oro-mucosal drug delivery player SUDA Pharmaceuticals Ltd (ASX:SUD) notified that the Therapeutic Goods Administration (TGA) review for ZolpiMistTM is expected to be completed by Q4 2020, subject to the TGA feedback.
SUDA added that the TGA is continuing with the review of additional data submitted by the company for ZolpiMistTM, which supports the quality of the product being produced using the new active pharmaceutical ingredient (API) supplier and manufacturer.
The Company will also share this data with its current and future partners to back their regulatory submissions.
SUD is trading with a rise of ~6.5 per cent at $0.049 as at 11:54 AM AEST on 12th May 2020.